Genomic Tool Could Make Precision Medicine More Precise for More People

October 26, 2017
Genomic Tool Could Make Precision Medicine More Precise for More People
Researchers say a new an open-source genomic tool they developed is designed to help identify genetic variants that could cause cancer when normal tissue is not available or feasible to sequence--and help expand the reach of precision medicine to more diverse groups of people. [Source: iStock/© Gio_tto]

Precision medicine based on tumor-only sequencing is more precise for people of European decent—and less precise for those whose ancestry is from Latin America, Africa and Asia, according to a study.

Researchers from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC), led the study, titled “A method to reduce ancestry related germline false positives in tumor only somatic variant calling  and published October 19 in BMC Medical Genomics.

In the study, the researchers also discussed their development of an open-source genomic tool designed to help identify genetic variants that could cause cancer when normal tissue is not available or feasible to sequence.

The tool is named LumosVar—derived from the incantation “Lumos Maxima,” which produced a blinding flash of light from the tip of the wand in the world of Harry Potter, starting in the film “Harry Potter and the Prisoner of Azkaban.” The researchers cautioned, however, that LumosVar is not precise enough to pinpoint which anti-cancer drugs to give individual patients.

"The field of precision medicine isn't taking into account population differences,” John D. Carpten, Ph.D., director of the Institute of Translational Genomics at the Keck School of Medicine of USC, and one of the study's lead authors, said in a statement. “The approaches being used are imprecise when you look at very specific populations.”

"Tumor-only sequencing in patients from populations that have undergone rapid expansion significantly decreases the precision of precision medicine,” Dr. Carpten added. “Importantly, the greater impact will be on individuals from underrepresented communities.”

He and the other researchers cited the need to sequence more people from more diverse parts of the world. Most people worldwide who have undergone whole-genome sequencing are of European decent, biasing existing databases used to exclude false-positive variants. Yet European ancestry has the fewest genetic variants, especially individuals with roots in Scandinavia. Individuals with origins in less developed parts of the world have the most genetic variants, with individuals from Bangladesh having among the world's most diverse genomes.

Another challenge the researchers cited is that many hospitals collect tumor tissue for research purposes without collecting normal tissue for comparison, especially in underdeveloped nations.

“It is very difficult to identify a somatic, or potentially cancer-causing, variant when you don't have a germline, or normal, sample," said Rebecca Halperin, Ph.D., a TGen assistant research professor and the study's other lead author. “You get more false positives—those genetic variants that don't cause cancer—from populations with non-European ancestry.”

To help sort out false positives, Dr. Halperin and David W. Craig, Ph.D., the study's senior author and Vice Chair of the Keck School of Medicine of USC's Department of Translational Genomics, co-created LumosVar. The Bayesian tumor only caller is designed to leverage differences in allelic frequency between somatic and germline variants in impure tumors.

The researchers used simulated data to systematically examine how copy number alterations, tumor purity, and sequencing depth should affect the sensitivity of LumosVar, then evaluated the tool by using real data.

“We have clearly demonstrated that LumosVar has improved positive predictive value in calling somatic variants compared to database filtering, which is the most commonly used approach with unmatched tumor samples,” the study added. “When analyzing archival samples in a research setting, we believe LumosVar would be of great utility.”

The study produced what the research team called a surprising finding: Rapid population expansion over millennia in Africa, as in South America and Asia, turns out to have driven increased genetic diversity among individuals. Researchers assumed that because all modern humans across the globe can be genetically traced back to ancestors from Africa, those with African ancestry would be more genetically diverse, and those populations who spread elsewhere across the globe would, as descendants of more recent common ancestors, became less genetically diverse.

"The added complexity of identifying inherited genetic changes surprised me and many others we have shared these findings with," said Dr. Craig, who also is a Professor and Co-Director of the Institute of Translational Genomics at the Keck School of Medicine of USC.

The study was funded by The Ben & Catherine Ivy Foundation and by the Multiple Myeloma Research Foundation.